<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120710">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531374</url>
  </required_header>
  <id_info>
    <org_study_id>10037989DOC REV 1C</org_study_id>
    <nct_id>NCT01531374</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement</brief_title>
  <official_title>Medtronic CoreValve® Continued Access Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve®
      System in the treatment of symptomatic severe aortic stenosis in subjects who have a
      predicted very high risk and high risk for aortic valve surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Death or Major Stroke</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular and Cerebrovascular Event (MACCE)-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>MACCE is defined as a composite of:
All-cause death
Myocardial infarction (MI)
All stroke, and
Reintervention (defined as any cardiac surgery or percutaneous reintervention catheter procedure that repairs, otherwise alters or adjusts, or replaces a previously implanted valve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of individual MACCE components</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events (MAE)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conduction disturbance requiring permanent pacemaker implantation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA class</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distance walked during 6-minute walk test (6MWT)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of days alive out of hospital versus total days alive</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) change</measure>
    <time_frame>5 years</time_frame>
    <description>Using the following measures:
Kansas City Cardiomyopathy Questionnaire (KCCQ)
SF-12
EuroQoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of valve performance</measure>
    <time_frame>5 years</time_frame>
    <description>Using the following measures:
Transvalvular mean gradient
Effective orifice area
Degree of aortic valve regurgitation (transvalvular and paravalvular)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic valve disease hospitalization</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular deaths and valve-related deaths</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strokes (of any severity) and Transient Ischemic Attacks (TIAs)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index procedure related MAEs</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of index procedure hospital stay</measure>
    <time_frame>Admission to discharge</time_frame>
    <description>The length of index procedure hospital stay will be summarized for all subjects. Descriptive statistics will be provided. The endpoint is descriptive and no statistical hypothesis test will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Admission to discharge</time_frame>
    <description>Defined as:
Successful vascular access, delivery and deployment of the device, and successful retrieval of the delivery system,
Correct position of the device in the proper anatomical location (placement in the annulus with no impedance on device function),
Intended performance of the prosthetic valve (aortic valve area &gt; 1.2 cm2 for 26, 29 and 31mm valves, ≥ 0.9 cm2 for 23mm valve (by echocardiography using the continuity equation) and mean aortic valve gradient &lt; 20 mmHg or peak velocity &lt; 3 m/sec, without moderate or severe prosthetic valve aortic regurgitation)
Only one valve implanted in the proper anatomical location</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>Admission to discharge</time_frame>
    <description>Defined as device success and absence of in-hospital MACCE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of prosthetic valve dysfunction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1690</enrollment>
  <condition>Severe Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Extreme Risk: TAVI Iliofemoral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extreme Risk: TAVI Non-Iliofemoral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk: TAVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)</intervention_name>
    <arm_group_label>Extreme Risk: TAVI Iliofemoral</arm_group_label>
    <arm_group_label>Extreme Risk: TAVI Non-Iliofemoral</arm_group_label>
    <arm_group_label>High Risk: TAVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. High Risk: Subject must have co-morbidities such that one cardiologist and two
             cardiac surgeons agree that predicted risk of operative mortality is ≥15% (and
             predicted operative mortality or serious, irreversible morbidity risk of &lt; 50%) at 30
             days.

             OR

             Extreme Risk: Subject must have co-morbidities such that one cardiologist and two
             cardiac surgeons agree that medical factors preclude operation, based on a conclusion
             that the probability of death or serious morbidity exceeds the probability of
             meaningful improvement. Specifically, the predicted operative risk of death or
             serious, irreversible morbidity is ≥ 50% at 30 days.

          2. Subject has senile degenerative aortic valve stenosis with:

               -  Mean gradient &gt; 40 mmHg, or jet velocity greater than 4.0 m/sec by either
                  resting or dobutamine stress echocardiogram, or simultaneous pressure recordings
                  at cardiac catheterization (either resting or dobutamine stress), AND

               -  An initial aortic valve area of ≤ 0.8 cm2 (or aortic valve area index ≤ 0.5
                  cm2/m2) by resting echocardiogram or simultaneous pressure recordings at cardiac
                  catheterization

          3. Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New
             York Heart Association (NYHA) Functional Class II or greater.

          4. The subject or the subject's legal representative has been informed of the nature of
             the trial, agrees to its provisions and has provided written informed consent as
             approved by the IRB of the respective clinical site.

          5. The subject and the treating physician agree that the subject will return for all
             required post-procedure follow-up visits.

        Exclusion Criteria:

        Clinical

          1. Evidence of an acute myocardial infarction ≤ 30 days before the intended treatment.

          2. Any percutaneous coronary or peripheral interventional procedure performed within 30
             days prior to the MCS TAVI procedure including bare metal and drug eluting stents.

          3. Blood dyscrasias as defined: leukopenia (WBC &lt; 1000mm3), thrombocytopenia (platelet
             count &lt;50,000 cells/mm3), history of bleeding diathesis or coagulopathy.

          4. Untreated clinically significant coronary artery disease requiring revascularization.

          5. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or
             mechanical hemodynamic support.

          6. Need for emergency surgery for any reason.

          7. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) &lt; 20%
             as measured by resting echocardiogram.

          8. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack
             (TIA).

          9. End stage renal disease requiring chronic dialysis or creatinine clearance &lt; 20
             cc/min.

         10. Active GI bleeding that would preclude anticoagulation.

         11. A known hypersensitivity or contraindication to any of the following which cannot be
             adequately pre-medicated:

               -  Aspirin

               -  Heparin (HIT/HITTS) and bivalirudin

               -  Nitinol (titanium or nickel)

               -  Ticlopidine and clopidogrel

               -  Contrast media

         12. Ongoing sepsis, including active endocarditis.

         13. Subject refuses a blood transfusion.

         14. Life expectancy &lt; 12 months due to associated non-cardiac co-morbid conditions.

         15. Other medical, social, or psychological conditions that in the opinion of an
             Investigator precludes the subject from appropriate consent.

         16. Severe dementia (resulting in either inability to provide informed consent for the
             trial/procedure, prevents independent lifestyle outside of a chronic care facility,
             or will fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits).

         17. Currently participating in an investigational drug or another device trial.

         18. Symptomatic carotid or vertebral artery disease.

             Anatomical

         19. High Risk:Native aortic annulus size &lt; 20 mm or &gt; 29 mm per the baseline diagnostic
             imaging (until 23mm valve enrollment completion/closure in the CoreValve® US Pivotal
             Trial-High Risk Cohort)

             OR

             Extreme Risk: Native aortic annulus size &lt; 18 mm or &gt; 29 mm per the baseline
             diagnostic imaging. (High risk and extreme risk upon 23mm valve enrollment
             completion/closure in the CoreValve® US Pivotal Trial-High Risk Cohort)

         20. Pre-existing prosthetic heart valve any position.

         21. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant
             aortic regurgitation (3-4+)).

         22. Moderate to severe (3-4+) or severe (4+) mitral or severe (4+) tricuspid
             regurgitation.

         23. Moderate to severe mitral stenosis.

         24. Hypertrophic obstructive cardiomyopathy.

         25. Echocardiographic evidence of new or untreated intracardiac mass, thrombus or
             vegetation.

         26. Severe basal septal hypertrophy with an outflow gradient.

         27. Aortic root angulation (angle between plane of aortic valve annulus and horizontal
             plane/vertebrae) &gt; 70° (for femoral and left subclavian/axillary access) and &gt; 30°
             (for right subclavian/axillary access).

         28. Ascending aorta diameter &gt;43 mm if the aortic annulus diameter is 23-29 mm; ascending
             aortic diameter &gt; 40 mm if the aortic annulus diameter is 20-23 mm; or an ascending
             aorta diameter &gt; 34 mm if the aortic annulus diameter is 18-20 mm (Extreme Risk only
             until 23 mm valve enrollment completion/closure in the CoreValve® US Pivotal
             Trial-High Risk Cohort).

         29. Congenital bicuspid or unicuspid valve verified by echocardiography.

         30. Sinus of valsalva anatomy that would prevent adequate coronary perfusion.

             Vascular

         31. Transarterial access not able to accommodate an 18Fr sheath.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey J Popma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David H Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Good Samaritan</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California University Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center / Georgetown Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Health System / Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South/Terrebonne General</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center Cardiovascular Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital/ Long Island Jewish Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University - Baptist Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals - Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center - The Richard M. Ross Heart Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute at St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital - The Methodist DeBakey Heart &amp; Vascular Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Healthcare</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center - Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 26, 2016</lastchanged_date>
  <firstreceived_date>February 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Critical Aortic Stenosis</keyword>
  <keyword>Severe Aortic Stenosis</keyword>
  <keyword>Extreme Risk</keyword>
  <keyword>High Risk</keyword>
  <keyword>Aortic Valve Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
